Outcome of Board Meeting
NGLFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 11.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NGL Fine-Chem Limited reported strong FY26 results with standalone revenue growing 36% to Rs 48,877 lakhs and PAT jumping 130% to Rs 4,163 lakhs versus FY25. Consolidated revenue reached Rs 50,095 lakhs with PAT of Rs 4,813 lakhs. The Board approved audited financial results with an unmodified (clean) auditor opinion from Manek & Associates. A final dividend of Rs 1.75 per share (35% on face value of Rs 5) aggregating to Rs 108.12 lakhs was recommended. Key director appointments include reappointment of Mr. Rajesh Lawande as Whole-Time Director and Mrs. Sarala Menon as Independent Director, both for 5-year terms subject to shareholder approval. Internal auditor KD Practice Consulting and Cost Auditor Sanghavi Randeria were also appointed for FY27.
The company delivered exceptional double-digit growth in both revenue and profits. The clean audit opinion and shareholder-friendly dividend signal financial health. However, investors should note rising trade receivables (Rs 12,547 lakhs vs Rs 7,977 lakhs) and increased capital work-in-progress (Rs 9,457 lakhs) indicating expansion capex. Related party disclosure notes Mr. Rajesh Lawande is related to Mrs. Ajita Nachane.